16th week of 2009 patent applcation highlights part 44 |
Patent application number | Title | Published |
20090099026 | METHOD OF PROCESSING WIDTH OF SUPERCONDUCTING WIRE ROD - A method of processing width of a superconducting wire rod is provided, in which slit processing is performed to a superconducting wire rod formed using a wide substrate, without deteriorating the superconducting feature and at high production efficiency. The method includes a step of preparing the superconducting wire rod and a step of cutting the superconducting wire rod by processing portions each having two opposing cutting portions. At least two sets of the processing portions are arranged adjacent to each other with a distance in a width direction of the superconducting wire rod so that the superconducting wire rod is interposed between the two cutting portions. Contacting positions of the cutting portions contacting one surface of the superconducting wire rod are externally positioned in the width direction of the superconducting wire rod relative to contacting positions of the cutting portions contacting the other surface of the superconducting wire rod. | 2009-04-16 |
20090099027 | Methods of Modifying Support Surfaces for the Immobilization of Particles and the Use of the Immobilized Particles for Analyzing Nucleic Acids - Methods of modifying a nucleophilic surface of a support are described. The methods involve reacting a multifunctional electrophilic reagent with nucleophilic groups on the surface of the support. The resulting electrophilic surface can be used for the covalent attachment of particles (e.g. beads) having nucleophilic functional groups. For example, nucleic acid templates with nucleophilic (e.g., amine) groups can be attached to a surface of the particles. The nucleophilic groups on the nucleic acid templates can then be used to attach the particles to the modified surface of the support. The resulting support-bound particles can be used to analyze (e.g., sequence) the nucleic acid templates on the particles. | 2009-04-16 |
20090099028 | Protein binding miniature proteins and uses thereof - In certain aspects, the present invention provides miniature proteins resulted from a protein scaffold such as an avian pancreatic polypeptide that can be modified by substitution of at least one amino acid residue. In other aspects, the present invention provides diagnostic and therapeutic uses of these miniature proteins. | 2009-04-16 |
20090099029 | Methods and substrates for conducting assays - The present invention relates to methods of conducting kinase assays using a myelin basic protein subtrate and a tyrosine kinase. Also provided herein are compositions that include myelin basic protein and a tyrosine kinase. Illustrative embodiments of these assays are performed on a microarray. In another embodiment, provided herein is a universal substrate that includes myelin basic protein. | 2009-04-16 |
20090099030 | Method of detecting mutations in the gene encoding cytochrome P450-2C9 - The present invention describes a method for the simultaneous identification of two or more mutations located in the gene encoding Cytochrome P450-2C9. Multiplex detection is accomplished using multiplexed tagged allele specific primer extension (ASPE) and hybridization of such extended primers to a probe, preferably an addressable anti-tagged support. | 2009-04-16 |
20090099031 | Genetic package and uses thereof - The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications. | 2009-04-16 |
20090099032 | HIGHLY SENSITIVE PROTEOMIC ANALYSIS METHODS, AND KITS AND SYSTEMS FOR PRACTICING THE SAME - Methods of determining whether a sample includes one or more analytes, particularly proteinaceous analytes, of interest are provided. In the subject methods, an array of binding agents, where each binding agent includes an epitope binding domain of an antibody, is contacted with the sample. In many embodiments, contact occurs in the presence of a metal ion chelating polysaccharide, e.g., a pectin. Following contact, the presence of binding complexes on the array surface are detected and the resultant data is employed to determine whether the sample includes the one or more analytes of interest. Also provided are kits, systems and other compositions of matter for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including proteomic applications such as protein expression analysis, e.g., differential protein expression profiling. | 2009-04-16 |
20090099033 | In vitro screening and evolution of proteins - The present invention provides a composition which links genotype and phenotype and provides a method for in vitro protein evolution and screening using said composition. The invention also facilitates the identification and isolation of proteins with selected properties from large pools of proteins. The composition and method of the invention can be used with eukaryotic (both mammalian and plant) and prokaryotic translation systems. | 2009-04-16 |
20090099034 | Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers - This invention provides methods for amplifying, detecting, measuring, and identifying miRNAs from biological samples, particularly limited amounts of a biological sample. miRNAs that are differentially expressed in tumor samples and normal tissues are useful as cancer biomarkers for cancer diagnostics. | 2009-04-16 |
20090099035 | OLIGONUCLEOTIDE ARRAYS FOR HIGH RESOLUTION HLA TYPING - Arrays of HLA Class I oligonucleotide probes on a solid support are provided, wherein the probes are sufficient to represent at least 80% of the known polymorphisms in exons 2 and 3 of the HLA Class I locus. | 2009-04-16 |
20090099036 | METHODS AND COMPOSITIONS FOR SCREENING GLYCAN STRUCTURES - The present invention relates to methods and compositions for screening of glycan structures. In particular, the present invention provides methods and compositions for global profiling of glycoprotein states by utilizing a glycoprotein microarray format. | 2009-04-16 |
20090099037 | Genomic Screen for Epigenetically Silenced Genes Associated With Cancer - A method of identifying epigenetically silenced genes, e.g., methylation silenced genes, in cancer cells is provided. In addition, methods of identifying a cancer by detecting epigenetic silencing of gene expression are provided, as are methods of treating a subject having such a cancer, for example, a colorectal cancer and/or gastric cancer. Reagents for practicing such methods also are provided. | 2009-04-16 |
20090099038 | CELL LINE, SYSTEM AND METHOD FOR OPTICAL-BASED SCREENING OF ION-CHANNEL MODULATORS - A variety of applications, systems, methods and constructs are implemented for use in connection with screening of ion-channel modulators. Consistent with one such system, drug candidates are screened to identify their effects on cell membrane ion channels and pumps. The system includes screening cells having light responsive membrane ion switches, voltage-gated ion switches and fluorescence producing voltage sensors. A chemical delivery device introduces the drug candidates to be screened. An optical delivery device activates the light responsive ion switches. An optical sensor monitors fluorescence produced by the voltage sensors. A processor processes data received from the optical sensor. A memory stores the data received from the optical sensor. | 2009-04-16 |
20090099039 | BINARY-COUPLED PROBE ARRAY, BIOCHIP, AND METHOD OF FABRICATION - A binary-coupled type probe array for analyzing components of a biological sample using probes, a biochip, and a method of fabricating the same, are provided. The binary-coupled probe array can include a substrate, a plurality of first probes immobilized on a top surface of the substrate, and a plurality of second probes immobilized on a bottom surface of the substrate. | 2009-04-16 |
20090099040 | DEGENERATE OLIGONUCLEOTIDES AND THEIR USES - The present invention provides a plurality of oligonucleotides comprising a semi-random sequence, wherein the semi-random sequence comprises degenerate nucleotides that are substantially non-complementary. Also provided are methods for using the plurality of oligonucleotides to amplify a population of target nucleic acids. | 2009-04-16 |
20090099041 | METHODS FOR MAKING NUCLEOTIDE PROBES FOR SEQUENCING AND SYNTHESIS - Compositions and methods for making a plurality of probes for analyzing a plurality of nucleic acid samples are provided. Compositions and methods for analyzing a plurality of nucleic acid samples to obtain sequence information in each nucleic acid sample are also provided. | 2009-04-16 |
20090099042 | Reverse Two-Hybrid System for Identification of Interaction Domains - The present invention provides methods for producing allele libraries and vectors for producing these libraries. The present invention also provides methods of identifying interaction domains between proteins. The vectors, kits, and methods of the present invention suitably utilize recombinational cloning to efficiently generate and screen full-length mutant alleles of target sequences of interest. | 2009-04-16 |
20090099043 | Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions - The present invention provides a PCR based high-throughput method for preparing full-sites siRNA polynucleotide pool, comprising: DNase I random digestion; Loop-1 phosphate linker ligation; single PCR amplification; a type III restriction/modification enzyme digestion; blunt ending; Loop-2 phosphate linker ligation; double primer PCR; FokI digestion and cloning into an siRNA expression vector. The present invention enables the use of a type III restriction/modification enzyme linkers mediated PCR method for high-throughput preparing an siRNA polynucleotide pool, in which the functional length of siRNAs can be controllably distributed from 19-23 bp, thus completely mimic the natural siRNA length diversity, specially suitable for RNAi therapeutic targets screening. The present invention overcomes the bottlenecks and drawbacks of conventional siRNA polynucleotide pool construction technologies. | 2009-04-16 |
20090099044 | Nanoparticles and Method to Control Nanoparticle Spacing - Disclosed herein are novel nanoparticles, particularly metal nanoparticles, such as gold nanoparticles. According to one embodiment of a method disclosed herein nanoparticles are functionalized via ligand exchange reactions. Also disclosed is a method for controlling nanoparticle spacing to produce nanoparticle arrays having defined spacing. Such nanoparticles and arrays thereof are particularly useful in nanoelectronics, nanophotonics, catalysis, sensors, and biotaggents. | 2009-04-16 |
20090099045 | METHODS AND DEVICES FOR MOLECULAR ASSOCIATION AND IMAGING - The present invention is directed to devices and methods for molecular association, particularly to devices and methods for hybridization of nucleic acids utilizing temperature gradients and imaging thereof. In one aspect, a molecular hybridization system generally includes a substrate having a plurality of molecular probes attached thereto, the plurality of probes being generally present in multiple copies arranged in localized formations on the surface of the substrate. The molecular hybridization system further generally includes a chamber that encloses the plurality of molecular probes such that a fluid containing sample may be applied and kept in contact with the substrate having the probes thereon. The molecular hybridization system also includes a temperature affecting system that generally produces at least one desired temperature on the surface of the substrate and in the adjacent fluid within the chamber. | 2009-04-16 |
20090099046 | METHODS, DRILLING FLUIDS AND DRILLING FLUID ADDITIVES FOR LIMITING TAR SAND ACCRETION ON METAL SURFACES - Drilling fluids, drilling fluid additives and methods for oil well drilling feature quaternary ammonium salts and act to reduce accretion of bituminous material on metal surfaces of drilling equipment. | 2009-04-16 |
20090099047 | Fusing Materials For Prevention of Lost Circulation - A method is given for reducing fluid loss in downhole operations such as drilling and completion. A composition containing a fusing solid is injected into the fluid loss flow path; the fusing solid fuses at formation temperature when the injection pressure is released and the formation matrix surfaces forming the flow path close on the composition. The fusing solid is gilsonite, or a similar material, or resin coated particles. The composition may optionally contain one or more of fibers, flakes, an activator, and a dispersant. | 2009-04-16 |
20090099048 | FUNCTIONAL FLUID COMPOSITION FOR IMPROVING LUBRICITY OF A BRAKING SYSTEM - The functional fluids of the present invention comprise about 50 parts by weight to about 99 parts by weight of a glycol component and about 0.3 parts by weight to about 10 parts by weight of one or more additives including a phosphate content. Desirably, in one aspect of this invention, the functional fluid composition exhibits an average scar width according to ASTM D 2670 (100 lb break-in for 1 min, 200 lb load for 30 minutes) that ranges from about 0.05 mm to about 0.45 mm, an average tooth count according to ASTM D 2670 (100 lb break-in for 1 min, 200 lb load for 30 minutes) of less than about 15, or both. | 2009-04-16 |
20090099049 | LUBRICATING OIL COMPOSITIONS - Reaction products of an acidic organic compound, a boron compound, and an alkoxylated amine and/or alkoxylated amide. Also disclosed are lubricating oil compositions and fuel compositions containing the reaction products. | 2009-04-16 |
20090099050 | FACIAL CLEANSING POWDER COMPOSITION - The invention provides a facial cleansing powder composition exhibiting good latherability even when used with hard water, the composition containing, as a substitute for edetic acid, an environmentally acceptable metal-sequestering agent which is readily incorporated into facial cleansing powder. The facial cleansing powder composition contains a facial cleansing powder base, phytic acid, and starch powder, wherein the phytic acid is supported on the starch powder. The amount of phytic acid is preferably 0.01 to 2.0 wt. %. Preferably, phytic acid is supported on starch powder by mixing an aqueous phytic acid solution with starch powder and drying the mixture. | 2009-04-16 |
20090099051 | Aqueous fluoride compositions for cleaning semiconductor devices - The present invention relates to dilute fluoride solutions and methods for cleaning plasma etch residue from semiconductor substrates including such dilute solutions. The compositions and methods according to the invention can advantageously provide both cleaning efficiency and material compatibility. | 2009-04-16 |
20090099052 | PRODUCT FOR TREATING A TOILET FLUSH CISTERN AND BOWL - A liquid additive product includes at least one acid, intended, in combination with the water contained in a toilet flush cistern of a WC, to constitute an agent for treating polluting elements contained in the cistern, characterized in that the viscosity of the additive product is less than 500 mPa·s; wherein this acid is an organic acid, the concentration of which is at least equal to 30% by weight. A treating agent consisting of the additive product and the water contained in the cistern; wherein the concentration of this additive product, in the water of the cistern, is between 100 ppm and ppm, is also disclosed. | 2009-04-16 |
20090099053 | GRAFT POLYMER WITH HYDROCARBON GROUP AND METHOD FOR PRODUCING THE SAME - Provided is a polymer-based detergent builder which is capable of effectively suppressing deposition of a surfactant, and effectively preventing soil re-deposition, even in washing using high hardness water. Specifically, the present invention solves the above problem by a graft polymer with a hydrocarbon group made by graft polymerization of monomer components containing a hydrophilic monomer having an anionic group or a hydroxyl group, on a polyoxyalkylene-based compound represented by the following formula (1): | 2009-04-16 |
20090099054 | METHOD FOR FORMULATING A REDUCED PHOSPHORUS BRANDED CLEANING PRODUCT OR CLEANING SYSTEM - A phosphorus-containing cleaning product manufactured or sold in association with a brand may be replaced by a substitute similarly-branded cleaning product or cleaning system containing less phosphorus-containing compound, and containing (or used with a water treatment product containing) sufficient magnesium compound to provide commercially acceptable cleaning performance when the substitute cleaning product contains or is used with hard water. | 2009-04-16 |
20090099055 | Solid Textile Care Composition Based On Soap - A solid textile-care composition having a matrix of soap and, distributed therein, a textile-care compound and a perfume. Also, textile-softening laundry detergents or cleaning agents containing the textile-care composition. | 2009-04-16 |
20090099056 | Protease Variants and Compositions - The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved wash performance in any detergent in comparison to their wild type parent enzymes. | 2009-04-16 |
20090099057 | Hard Surface Cleaning Composition - Improved highly aqueous, alkaline hard surface cleaning compositions useful in the cleaning of hard surfaces, particularly hard surfaces bearing greasy stains or soils. Preferred compositions comprise amine oxide as the sole surfactant constituent, an alkalinity constituent, preferably an alkanolamine and as the sole organic solvent constituent, an alkylene glycol phenyl ether, and water, optionally further including a dye and/or fragrance composition. The compositions provide excellent cleaning of greasy soils on hard surfaces. | 2009-04-16 |
20090099058 | FORMULATIONS WITH UNEXPECTED CLEANING PERFORMANCE INCORPORATING A BIODEGRADABLE CHELANT - A chelating composition suitable for low-temperature use or storage is disclosed. The chelating compositions include 20 to 70 wt. percent of a polar solvent and 30 to 80 wt. percent of a first component of the formula: (I) wherein R is a hydroxyalkyl group and each R′ is individually selected from the group consisting of hydrogen, unsubstituted or inertly substituted alkyl groups, carbonyl-containing alkyl groups, carboxylate-containing alkyl groups, hydroxyalkyl groups and alkoxy groups; R″ is selected from the group consisting of hydrogen, unsubstituted or inertly substituted alkyl groups; carbonyl-substituted alkyl groups, carboxylate-containing alkyl groups, hydroxyalkyl groups and alkoxy groups; M | 2009-04-16 |
20090099059 | METHOD FOR PRODUCING TRIMETHYLCYCLODODECATRIENE - The present invention relates to the preparation of trimethylcyclododecatriene in a continuous or batchwise process by trimerizing isoprene in the presence of a catalyst system and of a solvent. It is possible to isolate the resulting crude trimethylcyclododecatriene by means of distillation. The dimethylcyclooctadiene formed as a by-product may likewise be isolated from the crude product. | 2009-04-16 |
20090099060 | Modulation of line-1 reverse transcriptase - A reverse transcriptase encoded by L-1 (LINE-1) has been identified as a target molecule for treating or preventing cancers induced or mediated by this molecule. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptase in cells of the patients. The inhibitor or antagonist blocks lengthening of telomeres in telomerase negative cells. Methods and kits for detecting pathologically proliferating cells expressing L1RT are also disclosed. | 2009-04-16 |
20090099061 | SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS - A method is described for synthesizing and administering carotenoid compounds with improved antioxidant characteristics. In some embodiments, extension or improvement of conjugation may be employed in structural modification of carotenoids. In other embodiments, reduction of ring/chain steric hindrance may improve the lambda max, and hence, the overall antioxidant capability, of particular compounds. In other embodiments, introduction and/or increase in synthetic handles for conjugation may improve the stoichiometric ratios of conjugating moieties to the polyene backbone. The methods may be used to improve natural and/or synthetic compounds for medicinal application in the treatment of disease. | 2009-04-16 |
20090099062 | Pyrvinium For The Treatment of Cancer - The present invention concerns a pyrvinium compound or an analog thereof for the treatment of cancers. This compound inhibits Wnt activity in the cells of cancers such as adrenocortical, hepatocellular, hepatoblastoma, malignant melanoma, ovarian, Wilm's tumor, Barrett's esophageal, glioma, bladder, breast, gastric, head & neck, lung cell, mesothelioma, and cervical cancers. The present invention also provides a method for assaying for compounds that alter Wnt pathway activity. Also provided are methods for treating Wnt-related non-cancer disease states. | 2009-04-16 |
20090099063 | SSX-2 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES - The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4 | 2009-04-16 |
20090099064 | Derivatized insulin oligomers - The present invention provides oligomers of phosphorylated insulin and formulations thereof. The oligomeric derivatives of the invention exhibit pharmacodynamic properties that are significantly improved over native insulin or other intermediate-acting or basal insulins, for example NPH, Lantus or Detemir, in that they demonstrate a 4-fold higher therapeutic index and a 4-fold lower risk of hypoglycemia. The invention provides the advantage of protracted glycemic lowering and combines it with the advantage of reduced hypoglycaemic risk. The above is not a property of any presently-known or available basal or intermediate-acting insulin. In a further embodiment of the invention, formulations of oligomeric phosphorylated insulin are suitable for all routes of administration including inhalation, buccal absorption, subcutaneous injection, infusion or other technically proven routes for insulin administration. The invention additionally provides the advantage of a longer-acting formulation for inhalation between meals and at bedtime. Such longer-acting inhalable formulations are not presently available. | 2009-04-16 |
20090099065 | Acylated Single Chain Insulin - The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in one of the positions A12-A23 in the human insulin A-chain has been chemically modified by acylation. | 2009-04-16 |
20090099066 | Tissue specific peptide conjugates and methods - Cell-penetrating peptides useful for targeting a therapeutic compound to a selected mammalian tissue, methods for their identification, methods of forming conjugate compounds containing such peptides, and conjugates formed thereby are disclosed. The cell-penetrating peptides are 8 to 30 amino acid residues in length and consist of subsequences selected from the group consisting of RXR, RX, RB, and RBR; where R is arginine, B is β-alanine, and each X is independently —C(O)—(CHR | 2009-04-16 |
20090099067 | Glycosylated G-CSF - The invention relates to G-CSF molecules having certain O-linked oligosaccharide structures. | 2009-04-16 |
20090099068 | ON-GROWTH INHIBITING COMPOUNDS - An on-growth inhibiting agent, for the inhibition and/or prevention of on-growth of biological organisms on objects or living beings, includes at least one cyclotide, and a suitable carrier medium. A plant extract containing a mixture of cyclotides is also usable. | 2009-04-16 |
20090099069 | MODULATORS OF ALPHA-SYNUCLEIN TOXICITY - Disclosed are compositions and methods for modulating expression of genes that function at the step of ER of Golgi trafficking. Compounds that modulate expression of these genes of activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to threat of prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity. | 2009-04-16 |
20090099071 | SUGAR CHAIN-CONTAINING ALBUMIN, PRODUCTION METHOD THEREOF AND USE THEREOF - Glycosylated albumin as a drug carrier for a DDS targeting the liver (particularly kupffer's cell) can be provided by mutating a DNA encoding albumin to encode a mutant albumin containing a partial amino acid sequence permitting glycosylation modification by eukaryotic cell, preferably a consensus sequence of N-linked sugar chain, introducing an expression vector containing the mutant DNA into a host eukaryotic cell, preferably a host cell permitting addition of a high-mannose type sugar chain, culturing the obtained transformant, and recovering a glycosylated albumin protein from the obtained culture. | 2009-04-16 |
20090099072 | Motif of the Beclin Protein Which Interacts with Anti-Apoptotic Members of the Bcl-2 Protein Family, and Uses - The invention relates to a method of identifying modulators of programmed cell death, comprising an interaction between a motif of Beclin protein and an anti-apoptotic member of the family of Bcl-2 proteins and the detection of said interaction be means of fluorescence polarisation. The modulators identified on the basis of said method are administered to cancer patients in order to induce apoptotic- and/or autophagic-type programmed cell death. The invention also relates to a motif of the Beclin protein which can interact with an anti-apoptic member of the family of Bcl-2 proteins and to the use thereof in order to induce programmed cell death in a cancer patient. | 2009-04-16 |
20090099073 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2009-04-16 |
20090099074 | MODULATING FOOD INTAKE - The present disclosure relates to a conjugate comprising a PYY peptide or a functional derivative thereof which is coupled to a reactive group. Such a reactive group reacts with albumin so as to form a stable covalent bond therewith. The disclosure further provides methods of reducing water or food intake and reducing food intake between meals by administering such conjugates. | 2009-04-16 |
20090099075 | Chimeric Keratin-Binding Effector Proteins - The invention relates to chimeric keratin-binding effector proteins and their use in dermocosmetics. | 2009-04-16 |
20090099076 | OBG3 Globular Head and Uses Thereof - The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidermias, atherosclerosis, diabetes, and hypertension. | 2009-04-16 |
20090099077 | TREATMENT OF RETT SYNDROME AND OTHER DISORDERS - The invention relates to methods for treatment of Rett Syndrome and other disorders of synaptic function and maturation using IGF1, (1-3)IGF-1, (1-3)IGF-1 analog(s) and/or related therapeutic molecules. | 2009-04-16 |
20090099078 | Nogo Receptor Antagonists - Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides. | 2009-04-16 |
20090099079 | Novel Fungal Enzymes - This invention relates to novel enzymes and novel methods for producing the same. More specifically this invention relates to a variety of fungal enzymes. Nucleic acid molecules encoding such enzymes, compositions, recombinant and genetically modified host cells, and methods of use are described. The invention also relates to a method to convert lignocellulosic biomass to fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass. The invention also relates to a method to release cellular content by degradation of cell walls. The invention also relates to methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, biorefining, deinking and biobleaching of paper and pulp, and treatment of waste streams. | 2009-04-16 |
20090099080 | MITOCHONDRIA-TARGETED ANTI-TUMOR AGENTS - Described are mitochondria-targeted anti-tumor agents, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation. | 2009-04-16 |
20090099081 | SYNTHETIC AXMI-004 DELTA-ENDOTOXIN GENES AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided, particularly synthetically-derived coding sequences. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:9, 11, 13, 15, or 18, or the nucleotide sequence set forth in SEQ ID NO:1, 2, 4, 6, 7, 8, 10, 12, 14, 16, or 17, as well as variants and fragments thereof. | 2009-04-16 |
20090099082 | PRODUCTION OF POLYURETHANE FOAMS - The invention relates to a process for producing polyurethane foams, by frothing and drying mixtures of specific polyurethane dispersions and crosslinkers. | 2009-04-16 |
20090099083 | COMPOSITIONS FOR ELICITING AN IMMUNE RESPONSE AGAINST MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS - Provided are compositions and methods for stimulating an immune response against | 2009-04-16 |
20090099084 | Treatment - The invention provides use of a TSG-6 polypeptide, or a polynucleotide encoding an TSG-6 polypeptide, in the manufacture of a medicament for the treatment or prevention of a bone disease or condition associated with bone resorption by osteoclasts. | 2009-04-16 |
20090099085 | Amylin Derivatives - The present invention relates to novel amylin derivatives having a protracted action profile, to pharmaceutical compositions comprising these derivatives and to the use of the derivatives for the treatment of diseases related to obesity, diabetes and other metabolic disorders. | 2009-04-16 |
20090099086 | Activin-ActRIIa antagonists and uses for promoting bone growth - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 2009-04-16 |
20090099087 | Human kunitz-type inhibitor with enhanced antifibrinolytic activity - A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2). In another aspect, methods of treating a subject afflicted with cancer or a precancerous condition are described. Generally, the method includes administering to a subject in need of treatment an effective amount of a polypeptide. In some embodiments, the polypeptide comprises a KD1 domain of human TFPI-2. In some embodiments, the polypeptide comprises human TFPI-2, itself. In certain embodiments, the polypeptide is administered in an amount effective to induce apoptosis in tumor cells. | 2009-04-16 |
20090099088 | System for Inhibiting Pathogenicity in the Rice-Blast Fungus Magnaporthe Grisea | 2009-04-16 |
20090099089 | METHODS AND COMPOSITIONS FOR HEALING AND REPAIR OF ARTICULAR CARTILAGE - Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in the regeneration of functional repair of articular cartilage tissue. | 2009-04-16 |
20090099090 | HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES - HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients. | 2009-04-16 |
20090099091 | Oligopeptide Tyrosinase Inhibitors and Uses Thereof - Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Peptide sequences disclosed include KFEKKFEK and YRSRKYSSWY. | 2009-04-16 |
20090099092 | METHODS FOR STIMULATING FIBROBLAST PROLIFERATION USING SUBSTANCE P ANALOGS - Provided herein are methods and compositions for stimulating or promoting fibroblast proliferation. In one embodiment, provided herein are methods and compositions for promoting or enhancing wound healing. | 2009-04-16 |
20090099093 | Peptide Tyrosinase Inhibitors and Uses Thereof - Disclosed are peptides, which inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. The peptides are characterized by sequences RADRADC and PLG-OH. Methods of skin treatment are also provided, the methods further including use of a peptide characterized by the amino acid sequence SFLLRN. | 2009-04-16 |
20090099094 | Use of Somatostatin Agonists to Treat Medullary Thyroid Carcinoma - The present invention is directed to a method of determining a treatment to effectively combat medullary thyroid carcinoma and to suppress the secretion of calcitonin from medullary thyroid carcinoma cells. The present invention also provides a method of suppressing the secretion of calcitonin from medullary thyroid carcinoma cells and decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more somatostatin agonists. | 2009-04-16 |
20090099095 | Novel neuroprotective peptide - The field of the present invention is a novel neuroprotective peptide, pentinin, having neuroprotective properties. More particularly, the field of the present invention relates to the ability of pentinin (SEQ ID NO: 1) to affect endogenous undifferentiated stem cells to positively modulate neural damage and the use of such peptide for the treatment of disorders of the neural system. The present invention also relates to the manufacture of medicaments, methods of formulation and uses thereof. An intranasal delivery system for administration of pentinin is also described. | 2009-04-16 |
20090099096 | AZA-peptide protease inhibitors - The invention is related to compounds of Formula I: | 2009-04-16 |
20090099097 | Enzyme inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds. | 2009-04-16 |
20090099098 | PEPTIDE SUBSTANCE ENHANCING CAPILLARIES RESISTANCE, PHARMACEUTICAL COMPOSITION ON ITS BASE AND METHOD OF ITS APPLICATION - The invention is related to the medicinal means of correction of metabolic vascular syndrome and diseases, associated with disordered vascular wall permeability and capillaries fragility, and can be used as a means of enhancing capillaries resistance. There is proposed a peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO:1], revealing biological activity and capable of enhancing capillaries resistance. There is also proposed a pharmaceutical composition enhancing capillaries resistance, containing effective amount of peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO: 1] as its active base and pharmaceutically acceptable carrier. This pharmaceutical composition is in form for parenteral administration. There is proposed a method for prevention and/or treatment of disorders of microcirculation in organs and tissues, consisting in the administration to a patient of the pharmaceutical composition, containing peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO: 1] in the dose of 0.01-100 μg/kg of body weight at least once a day during a period necessary for attaining the therapeutic effect, such administration being performed parenterally. | 2009-04-16 |
20090099099 | Isoflavone Glycosides as Peroxisome Proliferator-Activated Receptor-alpha Modulator - A method of treating or preventing diseases related to modulation of PPAR-α in comprising administering to a human or other mammals in need of such treatment an effective amount of plant material derived from plants of the genera | 2009-04-16 |
20090099100 | Compositions and methods for treating amyloidosis - Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula | 2009-04-16 |
20090099101 | Drugs, foods or drinks with the use of algae-derived physiologically active substances - Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1): | 2009-04-16 |
20090099102 | Ginkgolides in the Treatment and Prevention of Ovarian Cancer - The present invention is directed to pharmaceutical compositions and nutritional supplements that contain large amount of ginkgolides, particularly ginkgolide A or B, and for which, the other components normally found in | 2009-04-16 |
20090099103 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER - The invention relates to a combination comprising an Erb-B and VEGF receptor inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination. | 2009-04-16 |
20090099104 | SUBSTITUTED INDAZOLES-O- GLUCOSIDES - Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed. | 2009-04-16 |
20090099105 | Content dependent inhibitors of cytidine deaminases and uses thereof - This invention relates to cytidine deaminase inhibitors (Cytidine deaminase inhibitors) of cytidine deaminases and uses thereof. | 2009-04-16 |
20090099106 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION - Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders. | 2009-04-16 |
20090099107 | Methods and Compositions for Inhibition of Nuclear Factor kappaB - A series of p105-based NF-κB super repressors, designated p-105(sr), have been designed. The p105(sr), no longer generates p50 and undergoes signal-induced degradation, effectively inhibiting all NF-κB activities. Additionally, p105(sr) significantly enhances tumor necrosis factor alpha (TNF-α)-mediated killing of MT1/2 skin papilloma cells when p50 homodimer activity is elevated. p105(sr) is an effective NF-κB super repressor with a broader range than other currently available IkBα super repressors. The novel repressor can be used in cells where a noncanical NF-κB activity is dominant or multiple NF-κB activities are activated. | 2009-04-16 |
20090099108 | OLIGONUCLEOTIDE DECOYS AND METHODS OF USE - The present invention describes reagents and methods for using a concatemerized double-stranded oligonucleotide molecules (CODN) for transcription factor decoys. In one embodiment, the concatemers consist of a variable number of end-to-end repeated copies of a short (more than 5, 10, 15, 20, 2, 3035, 40, 45, 50, 75, 100, or more by but generally less than about 3 kb) dsDNA containing a sequence or sequences that act as transcription factor decoys. The present invention also provides for the use of the polymers for CODN/polymer complexes to a specific cell type; thus the agent can be made organ, tissue and/or cell-type specific. In another embodiment, the present invention provides for use of the CODN's in vitro or in vivo, in isolated cells or intact animals in which specific blockade of transcription factors or delivery of DNA or other biological effector is desirable. In one embodiment, this includes use as a research tool, including studies of specific genes and studies to identify specific genes regulated by the transcription factors targeted. In another embodiment, the present invention provides for using polyamides for NF-kB-specific CODN delivery in the treatment of myocardial ischemia/reperfusion and myocardial infarction, heart failure and hypertrophy, cardioprotection, stroke, neuroprotection, sepsis, arthritis, asthma, heritable inflammatory disorders, cancer, heritable immune dysfunctions, inflammatory processes, whether caused by disease or injury or infection, oxidative stress to any organ whether caused by disease, surgery or injury. The decoys may be any transcription factors, including, but not limited to, NF-kB, AP-I, ATF2, ATF3, SP 1 and others. | 2009-04-16 |
20090099109 | INTERFERING RNAS AGAINST THE PROMOTER REGION OF P53 - The present invention relates to the inhibition of p53 transcription by interfering with the activity of a p53 promoter using inhibitory double-stranded RNAs. Use of these inhibitory RNAs in the treatment of cancers also is disclosed. | 2009-04-16 |
20090099110 | Antiviral oligonucleotides - Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action. | 2009-04-16 |
20090099111 | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure - The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention. | 2009-04-16 |
20090099112 | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure - The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention. | 2009-04-16 |
20090099113 | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure - The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention. | 2009-04-16 |
20090099114 | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure - The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention. | 2009-04-16 |
20090099115 | RNA INTERFERENCE MEDIATED INHIBITION OF MYC AND/OR MYB GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating Myc and/or Myb gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Myc and/or Myb gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of Myc and/or Myb (e.g., c-Myc, N-Myc, L-Myc, c-Myb, a-Myb, b-Myb, and v-Myb) genes. The small nucleic acid molecules are useful in the treatment of cancer and other diseases and disorders. | 2009-04-16 |
20090099116 | RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating c-Fos gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of c-Fos gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of c-Fos genes. The small nucleic acid molecules are useful in the treatment of cancer, proliferative diseases or conditions, inflammatory diseases or conditions, allergic diseases or conditions, infectious diseases or conditions, autoimmune diseases or conditions, or transplantation/allograft rejection in a subject or organism. | 2009-04-16 |
20090099117 | RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating myostatin (GDF8) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of myostatin gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of myostatin genes. | 2009-04-16 |
20090099118 | RNA INTERFERENCE MEDIATED INHIBITION OF STEAROYL-CoA DESATURASE (SCD) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Stearoyl-CoA desaturase (SCD) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of Stearoyl-CoA desaturase (SCD) genes. | 2009-04-16 |
20090099119 | RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating RAS, e.g. K-RAS, H-RAS, and/or N-RAS gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RAS, e.g. K-RAS, H-RAS, and/or N-RAS gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of RAS genes, such as K-RAS, H-RAS, and/or N-RAS. | 2009-04-16 |
20090099120 | RNA INTERFERENCE MEDIATED INHIBITION OF MUSCARINIC COLINERGIC RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of cholinergic muscarinic receptor genes, or other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3 (CHRM3). | 2009-04-16 |
20090099121 | RNA INTERFERENCE MEDIATED INHIBITION OF MATRIX METALLOPROTEINASE 13 (MMP13) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating matrix metalloproteinase (e.g., MMP13) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of MMP13 genes. | 2009-04-16 |
20090099122 | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE EPITHELIAL CELL GROWTH - This disclosure provides a method of inducing epithelial cell growth. The method includes administering an effective amount of a K-type CpG oligonucleotide, thereby inducing epithelial cell growth. The epithelial cell can be in vivo or in vitro. Methods are also provided for inducing wound healing in a subject. The methods include administering to the subject a therapeutically effective amount of at least on K-type CpG ODN. | 2009-04-16 |
20090099123 | Antisense microRNA and uses therefor - Provided herein are methods to suppress specificity protein (Sp) activity in a cell associated with a cell proliferative disease. The methods are effective to inhibit a microRNA in the cell using an antisense microRNA oligonucleotide which results in an increase in expression of a specificity protein (Sp) suppressor gene thereby inducing Sp degradation, apoptosis or growth arrest by releasing inhibitors of G2/M (Myt-1) or inhibition. Also provided are methods of treating a cancer using the antisense microRNA oligonucleotide. In addition the present invention provides antisense microRNA-27a oligonucleotides useful in the methods described herein. | 2009-04-16 |
20090099124 | SHORT INTERFERING RNA AS AN ANTIVIRAL AGENT FOR HEPATITIS C - Hepatitis C virus (HCV) is a major cause of chronic liver disease and affects over 270 million individuals worldwide. The HCV genome is a single-stranded RNA that functions as both a messenger RNA and replication template, making it an attractive target for the study of RNA interference. Double-stranded short interfering RNA (siRNA) molecules designed to target the HCV genome are disclosed herein. | 2009-04-16 |
20090099125 | PAN CANCER ONCOLYTIC VECTORS AND METHODS OF USE THEREOF - Replication-competent adenoviral vectors which selectively replicate in cancer cells are provided. The replication-competent viral vectors comprise an E2F responsive promoter and/or a telomerase promoter operatively linked to an adenoviral coding region. The replication-competent adenoviral vectors effectively replicate in a variety of types of cancer cells and find broad utility in the treatment of cancer. | 2009-04-16 |
20090099126 | Ribonucleoside Cyclic Acetal Derivatives for the Treatment of RNA-Dependent RNA Viral Infection - The present invention provides ribonucleoside 2′,3′-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2′,3′-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the ribonucleoside 2′,3′-cyclic acetals of the present invention. | 2009-04-16 |